|
|
|
|
|
|
|
M T W Th Fri |
|
16 October, 2026 |
|
|
sponsored by
|
|
|
|
Delegate the Groundwork. Free Your Schedule to Advance the Science.
|
| Are you losing days chasing records across systems and assembling evidence before an investigation can begin? Katalyze AI delegates the groundwork to agents that gather the evidence and draft reports for you, with every finding connected back to its source. You review the results, challenge them in plain language, and decide what happens next. Built for GxP environments, Katalyze offers solutions for Yield Optimization, Deviation Investigation, Tech Transfer, and Raw Material Characterization. |
|
|
|
|
|
|
|
|
|
|
|
|
|
It looks like HHS is pushing to allow compounding pharmacies to make popular wellness peptides. Even though there aren't many details yet, compounders appear to see this as a big win. Know more? Message Shelby, who follows all things compounding and peptides for us. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Maggie Fick
|
Paulo Fontoura took over as Sanofi’s global head of R&D in September after 16 years at Roche and a recent stint at AI drug discovery... | |
|
|
|
|
|
|
by Anna Brown
|
Eli Lilly secured EU regulatory backing for its oral GLP-1 pill orforglipron on Friday as it looks to catch up with competitor Novo’s Wegovy pill... | |
|
|
|
|
|
|
by Kyle LaHucik
|
City Therapeutics became the 26th biotech to complete an initial public offering in 2026 when it began trading Friday morning, adding to a boisterous rebound... | |
|
|
|
|
|
|
|
|
by Max Bayer, Robert Postings
|
The Chinese Ministry of Commerce is clamping down on the kinds of deals domestic companies can make, but the free-flowing licensing of drugs appears to... | |
|
|
|
|
|
|
by Kyle LaHucik, Max Bayer
|
Eli Lilly is interested in R&D efforts to “improve the profile of ibogaine,” the pharma giant’s neuroscience president said at a psychedelics conference Thursday. Carole... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about Microbiotica, Cyrano Therapeutics and Opus Genetics. HHS and FDA submit peptide policy for review:An “in&s |
|
|
